Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TILIA: Tozorakimab in Hospitalised Viral Lung Infection Requiring Supplemental Oxygen
jRCT2041220138Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- May 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in viral pneumonia comparing Tozorakimab IV plus standard of care with Placebo IV plus standard of care (2 arms). Primary endpoint: Composite of death or progression to IMV/ECMO by Day 28. Started May 2023; status: recruiting.
02
Drugs
tozorakimab
03
Conditions
viral pneumonia
Beyond the preview
Go deeper on jRCT2041220138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041220138.